{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003153","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.322490+00:00","generated_at":"2026-05-21T08:21:05.310452+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients","bullets":["Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.","Cash, equivalents & securities $112.7M as of Mar 31, down from $122.6M at Dec 31, 2024.","Imdusiran combo therapy functionally cured 8 cHBV patients to date; 2 received no interferon.","AB-101 oral PD-L1 inhibitor achieved 100% receptor occupancy in 11 of 13 healthy subjects at 40mg.","Moderna U.S. jury trial set for Sep 29, 2025; claim construction for Pfizer/BioNTech expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003153","json":"https://secwatch.observer/filing/0001171843-25-003153.json","markdown":"https://secwatch.observer/filing/0001171843-25-003153.md","text":"https://secwatch.observer/filing/0001171843-25-003153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/0001171843-25-003153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/f8k_051425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:21:05.310452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}